Denali Therapeutics Inc. Operating Cash Flow
Denali Therapeutics Inc. (DNLI) reported Operating Cash Flow of -$228.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Denali Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$97.00M.
- Denali Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$131.20M.
- Denali Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$98.54M.
- Denali Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$107.30M.
- Denali Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$412.60M.
- Denali Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$347.69M.
- Denali Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$357.99M.
- Denali Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$244.72M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$97.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$228.21M 10-Q · filed 2026-08-06 | -$326.74M derived: sum of 3 quarters · filed 2026-08-06 | -$434.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$131.20M 10-Q · filed 2026-05-07 | -$229.74M derived: sum of 2 quarters · filed 2026-05-07 | -$337.04M derived: sum of 3 quarters · filed 2026-05-07 | -$412.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$98.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$205.83M derived: sum of 2 quarters · filed 2026-02-26 | -$281.13M derived: sum of 3 quarters · filed 2026-08-06 | -$412.60M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$107.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$182.59M derived: sum of 2 quarters · filed 2026-08-06 | -$314.06M 10-Q · filed 2025-11-06 | -$397.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$75.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$206.77M 10-Q · filed 2026-08-06 | -$290.48M derived: sum of 3 quarters · filed 2026-08-06 | -$349.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$131.47M 10-Q · filed 2026-05-07 | -$215.18M derived: sum of 2 quarters · filed 2026-05-07 | -$274.32M derived: sum of 3 quarters · filed 2026-05-07 | -$365.54M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$83.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$142.85M derived: sum of 2 quarters · filed 2026-02-26 | -$234.07M derived: sum of 3 quarters · filed 2026-02-26 | -$347.69M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$59.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$150.36M derived: sum of 2 quarters · filed 2025-11-06 | -$263.98M 10-Q · filed 2025-11-06 | -$362.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$91.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$204.84M 10-Q · filed 2025-08-11 | -$303.50M derived: sum of 3 quarters · filed 2026-02-26 | -$390.86M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$113.62M 10-Q · filed 2025-05-06 | -$212.28M derived: sum of 2 quarters · filed 2026-02-26 | -$299.64M derived: sum of 3 quarters · filed 2026-02-26 | -$412.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$98.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$186.02M derived: sum of 2 quarters · filed 2026-02-26 | -$299.19M derived: sum of 3 quarters · filed 2026-02-26 | -$357.99M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$87.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$200.53M derived: sum of 2 quarters · filed 2024-11-06 | -$259.33M 10-Q · filed 2024-11-06 | -$332.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$113.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$171.97M 10-Q · filed 2024-08-01 | -$244.63M derived: sum of 3 quarters · filed 2025-02-27 | -$301.68M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$58.80M 10-Q · filed 2024-05-07 | -$131.47M derived: sum of 2 quarters · filed 2025-02-27 | -$188.51M derived: sum of 3 quarters · filed 2025-02-27 | -$231.41M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$72.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$129.71M derived: sum of 2 quarters · filed 2025-02-27 | -$172.61M derived: sum of 3 quarters · filed 2025-02-27 | -$244.72M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$57.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$99.94M derived: sum of 2 quarters · filed 2023-11-07 | -$172.05M 10-Q · filed 2023-11-07 | -$237.55M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$42.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$115.01M 10-Q · filed 2023-08-08 | -$180.50M derived: sum of 3 quarters · filed 2024-02-28 | -$221.94M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$72.11M 10-Q · filed 2023-05-08 | -$137.60M derived: sum of 2 quarters · filed 2024-02-28 | -$179.04M derived: sum of 3 quarters · filed 2024-02-28 | -$233.26M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$65.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$106.93M derived: sum of 2 quarters · filed 2024-02-28 | -$161.15M derived: sum of 3 quarters · filed 2024-02-28 | -$211.39M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$41.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$95.66M derived: sum of 2 quarters · filed 2022-11-03 | -$145.90M 10-Q · filed 2022-11-03 | $368.02M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$54.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$104.46M 10-Q · filed 2022-08-08 | $409.45M derived: sum of 3 quarters · filed 2023-02-27 | $409.54M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$50.24M 10-Q · filed 2022-05-05 | $463.68M derived: sum of 2 quarters · filed 2023-02-27 | $463.76M derived: sum of 3 quarters · filed 2023-02-27 | $420.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $513.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $514.00M derived: sum of 2 quarters · filed 2023-02-27 | $470.64M derived: sum of 3 quarters · filed 2023-02-27 | $416.15M 10-K · filed 2023-02-27 |
| 2020-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$43.27M derived: sum of 2 quarters · filed 2021-11-04 | -$97.76M 10-Q · filed 2021-11-04 | -$145.41M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$43.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$97.85M 10-Q · filed 2021-08-04 | -$145.49M derived: sum of 3 quarters · filed 2022-02-28 | -$175.93M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$54.49M 10-Q · filed 2021-05-05 | -$102.14M derived: sum of 2 quarters · filed 2022-02-28 | -$132.57M derived: sum of 3 quarters · filed 2022-02-28 | -$175.75M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$47.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$78.08M derived: sum of 2 quarters · filed 2022-02-28 | -$121.25M derived: sum of 3 quarters · filed 2022-02-28 | -$151.58M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$30.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$73.61M derived: sum of 2 quarters · filed 2020-11-05 | -$103.93M 10-Q · filed 2020-11-05 | -$10.75M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$43.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$73.50M 10-Q · filed 2020-08-07 | $19.69M derived: sum of 3 quarters · filed 2021-02-26 | -$15.13M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$30.32M 10-Q · filed 2020-05-07 | $62.86M derived: sum of 2 quarters · filed 2021-02-26 | $28.04M derived: sum of 3 quarters · filed 2021-02-26 | -$13.78M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $93.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $58.36M derived: sum of 2 quarters · filed 2021-02-26 | $16.54M derived: sum of 3 quarters · filed 2021-02-26 | $50.12M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$34.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$76.65M derived: sum of 2 quarters · filed 2019-11-06 | -$43.07M 10-Q · filed 2019-11-06 | -$61.41M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$41.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$8.25M 10-Q · filed 2019-08-06 | -$26.58M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2018-03-31 | $33.58M 10-Q · filed 2019-05-08 | $15.24M derived: sum of 2 quarters · filed 2020-02-27 | ||
| 2017-12-31 | -$18.34M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$76.64M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | -$58.30M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | -$71.91M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |